Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 5/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
Klaria Pharma Holding AB (publ.) Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | kr0.026 |
52 Week High | kr0.075 |
52 Week Low | kr0.01 |
Beta | 0.32 |
1 Month Change | -12.16% |
3 Month Change | 12.07% |
1 Year Change | 31.31% |
3 Year Change | -96.96% |
5 Year Change | n/a |
Change since IPO | -96.14% |
Recent News & Updates
Recent updates
Shareholder Returns
6FN | DE Pharmaceuticals | DE Market | |
---|---|---|---|
7D | -26.6% | -0.7% | -3.1% |
1Y | 31.3% | -18.1% | -0.5% |
Return vs Industry: 6FN exceeded the German Pharmaceuticals industry which returned -18.1% over the past year.
Return vs Market: 6FN exceeded the German Market which returned -0.5% over the past year.
Price Volatility
6FN volatility | |
---|---|
6FN Average Weekly Movement | 45.6% |
Pharmaceuticals Industry Average Movement | 5.3% |
Market Average Movement | 5.0% |
10% most volatile stocks in DE Market | 10.3% |
10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 6FN's share price has been volatile over the past 3 months.
Volatility Over Time: 6FN's weekly volatility has increased from 39% to 46% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2014 | 5 | Scott Boyer | www.klaria.com |
Klaria Pharma Holding AB (publ.) operates as a pharmaceutical company. It develops Sumatriptan for the treatment of migraine. The company also develops Epinephrine/Adrenaline, which is in Phase I clinical trial for the treatment of acute allergic reaction.
Klaria Pharma Holding AB (publ.) Fundamentals Summary
6FN fundamental statistics | |
---|---|
Market cap | €4.04m |
Earnings (TTM) | -€3.76m |
Revenue (TTM) | n/a |
-7.0x
P/S Ratio-1.1x
P/E RatioIs 6FN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
6FN income statement (TTM) | |
---|---|
Revenue | -kr6.53m |
Cost of Revenue | kr0 |
Gross Profit | -kr6.53m |
Other Expenses | kr35.74m |
Earnings | -kr42.27m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 22, 2024
Earnings per share (EPS) | -0.33 |
Gross Margin | 100.00% |
Net Profit Margin | 647.55% |
Debt/Equity Ratio | 0% |
How did 6FN perform over the long term?
See historical performance and comparison